Screener
Mineralys Therapeutics, Inc. MLYS Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
| Line item | Three Months Ended / March 31, 2026 | 2025 |
|---|---|---|
| Total operating expenses | 45,340 | 44,447 |
| Loss from operations | (45,340) | (44,447) |
| Interest income, net | 5,996 | 2,239 |
| Other income (expense) | 5 | (3) |
| Total other income, net | 6,001 | 2,236 |
| Net loss | $(39,339) | $(42,211) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.47) | $(0.79) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 82,834,752 | 53,163,551 |
Item 1. Financial Statements
FAQ
- What is Mineralys Therapeutics, Inc.'s other income (expense)?
- Mineralys Therapeutics, Inc. (MLYS) reported other income (expense) of $6M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s other income (expense) changed year-over-year?
- Mineralys Therapeutics, Inc.'s other income (expense) increased by 168.4% year-over-year, from $2.24M to $6M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s other income (expense)?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s other income (expense) has grown at a 111.8% compound annual growth rate (CAGR), from $1.68M to $15.95M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Mineralys Therapeutics, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude